Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja, Jahanzaib Bomsztyk, Joshua Atta, Maria Bygrave, Ceri Forbes, Adam Durairaj, Senthil Fernandes, Savio Taylor, James Paterson, Pamela Brearton, Gillian
Khwaja, Jahanzaib
Bomsztyk, Joshua
Atta, Maria
Bygrave, Ceri
Forbes, Adam
Durairaj, Senthil
Fernandes, Savio
Taylor, James
Paterson, Pamela
Brearton, Gillian
Citations
Altmetric:
Affiliation
University College London Hospital; University College London (Royal Free Campus), London; Imperial College Healthcare NHS Trust; The Dudley Group NHS Foundation Trust et al
Other Contributors
Publication date
2024-05-03
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty-one patients were reviewed, with a median of three prior lines of therapy. The median follow-up was 12 months (95% CI 4-19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty-eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis. � 2024 British Society for Haematology and John Wiley & Sons Ltd.
Citation
Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, Fernandes S, Taylor J, Paterson P, Brearton G, Crawley C, Sheehy O, Brown R, Soutar R, Garg M, Rydzewski A, Jamroziak K, Mahmood S, Wechalekar AD. Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis. Br J Haematol. 2024 May;204(5):1811-1815. doi: 10.1111/bjh.19286. Epub 2024 Jan 3. PMID: 38171355.